Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.57 |
| ▸ | PLAU | P00749 | 1/20 | 0.57 |
| ▸ | NCF1 | P14598 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | COMT | P21964 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4393939 | 0.92 | METAP2 (0.53) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL8236564 | 0.90 | METAP2 (0.52) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL7133311 | 0.89 | KCNH2 (0.56) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL4792326 | 0.89 | PLAU (0.55) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL7923339 | 0.89 | METAP2 (0.50) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL2484187 | 0.89 | METAP2 (0.55) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL8344154 | 0.88 | CD74 (0.48) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL3212638 | 0.88 | METAP2 (0.57) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL10437729 | 0.87 | METAP2 (0.49) | METAP2PLAUNCF1ALOX12ALDH1A1 | |
| SCHEMBL9220073 | 0.86 | CCR1 (0.65) | METAP2PLAUNCF1ALOX12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2009-09-10 | — | — | US | claimed |
| EP-1919894-B1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | PALUMED SA (FR) | 2014-10-08 | — | — | EP | disclosed |
| US-8324196-B2 | Polyquinoline derivatives and the therapeutic use thereof | PALUMED S.A. (FR) | 2012-12-04 | — | — | US | disclosed |
| US-20120277265-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) | 2012-11-01 | — | — | US | disclosed |
| US-8247396-B2 | Polyquinoline derivatives and therapeutic use thereof | PALUMED S.A. (FR) | 2012-08-21 | — | — | US | disclosed |
| US-8247396-B2 | Polyquinoline derivatives and therapeutic use thereof | PALUMED S.A. (FR) | 2012-08-21 | — | — | US | disclosed |
| EP-2289891-A2 | Novel polyquinoline derivates and the therapeutic use thereof | Palumed S.A. (FR) | 2011-03-02 | — | — | EP | disclosed |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | PALUMED S.A. (FR) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277265-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF | HTT, APP, PSEN1 | METAP2 2561/4885PLAU 3064/4885NCF1 1652/4885 |
| US-20090227626-A1 | NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF | HTT, UBQLN2, UBQLN1 | METAP2 4011/4885PLAU 3086/4885NCF1 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.